Acme Group
A fast growing fully integrated contract manufacturing company focused on innovation and quality serving the top Indian and global pharmaceutical companies. Acme strongly believes in fast growth combined with a focus on innovation and service.
Creation
Focused on innovation and quality, the group has also expanded into niche segments of Oral Hormones, both Sex Hormones and Levothyroxine, along with General Injectables - Liquids and Lyophilized.
Eminence
Since its inception in 2005 the Acme Group has become one of the leading contract manufacturing companies in the world and a preferred partner for top Indian and global companies including the top 25 Indian and 5 global MNCs.
Recognition
Audited and approved by various international regulatory agencies including UK-MHRA, EU-GMP, ANVISA, PICS, INVIMA, WHO-Geneva. Approvals across major countries in Asia, Africa, CIS and Latin Countries. US FDA filing is planned for Q2, 2018.
Growth
Fast growing and scalable, Acme has 2000+ highly skilled staff working in over 500,000 sq.ft manufacturing space across Northern India, producing 15 billion tablets, 3 billion capsules, 30 million ampoules and 12 million Lyo vials.
Acme Formulation
A state of the art manufacturing facility dedicated to producing Oral Solid Dosage including tablets / capsules/ oral contraceptives with a capacity of 3.5 billion tablets and 0.5 billion capsules per annum.
Acme Generics
Latest facility built across 18315 sq. meter manufacturing area dedicated to producing tablets/ capsules and Levothyroxine tablets with a capacity of 6 billion tablets from Levothyroxine block, 7 billion tablets and 2 billion capsules from general block.
